Tag: Hadlima

As an interchangeable biosimilar to Humira (adalimumab), Hadlima offers patients with certain chronic inflammatory diseases a potentially more affordable and widely available treatment option. This biologic medication provides a range of significant health benefits by targeting the underlying inflammation caused by an overactive immune system.

As of June 2025, Hadlima was designated as an interchangeable biosimilar for Humira, meaning it can be substituted by a pharmacist for the reference product in many US states. Understanding what is the use of Hadlima Pushtouch is crucial for patients managing various autoimmune and autoinflammatory conditions.